Linda L. Neuman - Feb 23, 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Medical Officer
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Feb 23, 2023
Transactions value $
$0
Form type
4
Date filed
2/24/2023, 05:25 PM
Previous filing
Jan 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +550K $0.00 550K Feb 23, 2023 Common Stock 550K $0.44 Direct F1

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.